Actively Recruiting
Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
Led by Peking University People's Hospital · Updated on 2025-09-23
30
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and providing a basis for clinical application.
CONDITIONS
Official Title
Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with vitiligo according to the Vitiligo Diagnosis and Treatment Consensus (2021 edition)
- Segmental or unclassified vitiligo stable for at least 6 months, or non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy
- Body surface area affected is 5% or more
- Willing to sign informed consent and undergo surgical treatment
- Aged between 8 and 65 years, both genders
You will not qualify if you...
- Severe visceral or infectious disease that makes surgery unsuitable
- Tendency to develop keloid scars
- Blood clotting (coagulation) disorders
- Unable to complete follow-up visits on time
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here